Why do many young cancer survivors forgo human papillomavirus vaccination?

byWileyTEM of papillomavirus. Credit: Public DomainAlthough young cancer survivors face an elevated risk for later developing cervical, oropharyngeal, and several other human papillomavirus (HPV

Updated on: January 08,2024

Why do many young cancer survivors forgo human papillomavirus vaccination?

byWileyTEM of papillomavirus. Credit: Public DomainAlthough young cancer survivors face an elevated risk for later developing cervical, oropharyngeal, and several other human papillomavirus (HPV

Updated on:January 08,2024

Identification of colony stimulating factor 1 receptor offers new strategy for cancer immunotherapy

by Zhang Nannan,Chinese Academy of SciencesIHMT-CSF1R-833 alters the macrophage polarization in M2 macrophages derived from RAW264.7 cells by inducing the M1 macrophage phenotype. Credit: Liang

Updated on: December 25,2023

Identification of colony stimulating factor 1 receptor offers new strategy for cancer immunotherapy

by Zhang Nannan,Chinese Academy of SciencesIHMT-CSF1R-833 alters the macrophage polarization in M2 macrophages derived from RAW264.7 cells by inducing the M1 macrophage phenotype. Credit: Liang

Updated on:December 25,2023

Social determinants of health affect racial disparity in prostate cancer mortality

by Elana GotkineWhen accounting for social determinants of health (SDOH), Black men with prostate cancer have lower prostate cancer-specific mortality (PCSM) than White men, according to a systematic

Updated on: December 26,2023

Social determinants of health affect racial disparity in prostate cancer mortality

by Elana GotkineWhen accounting for social determinants of health (SDOH), Black men with prostate cancer have lower prostate cancer-specific mortality (PCSM) than White men, according to a systematic

Updated on:December 26,2023

For cancer, a biopharmaceutical company and UC San Diego test another kind of immune cell

by Bradley J. Fikes, The San Diego Union-TribuneWhen the U.S. Food and Drug Administration approved the first cell-based gene therapies for cancer in 2017, advanced malignancies once seen as terminal

Updated on: December 18,2023

For cancer, a biopharmaceutical company and UC San Diego test another kind of immune cell

by Bradley J. Fikes, The San Diego Union-TribuneWhen the U.S. Food and Drug Administration approved the first cell-based gene therapies for cancer in 2017, advanced malignancies once seen as terminal

Updated on:December 18,2023

New bone cancer drug improves survival rates by 50% in preclinical trials

byUniversity of East AngliaCredit: Pixabay/CC0 Public DomainResearchers at the University of East Anglia have developed a new drug that works against all of the main types of primary bone cancer

Updated on: January 11,2024

New bone cancer drug improves survival rates by 50% in preclinical trials

byUniversity of East AngliaCredit: Pixabay/CC0 Public DomainResearchers at the University of East Anglia have developed a new drug that works against all of the main types of primary bone cancer

Updated on:January 11,2024

Clinical trial examines standard vs. extended lymph node removal for muscle-invasive bladder cancer

by SWOG Cancer Research NetworkCredit: Pixabay/CC0 Public DomainFinal results from the SWOG S1011 randomized Phase III clinical trial, published in theNew England Journal of Medicine, indicate p

Updated on: November 10,2024

Clinical trial examines standard vs. extended lymph node removal for muscle-invasive bladder cancer

by SWOG Cancer Research NetworkCredit: Pixabay/CC0 Public DomainFinal results from the SWOG S1011 randomized Phase III clinical trial, published in theNew England Journal of Medicine, indicate p

Updated on:November 10,2024

Imaging after one week on pembrolizumab may predict treatment response in advanced melanoma

by American Association for Cancer ResearchCredit: Pixabay/CC0 Public DomainImaging the tumors of patients with advanced melanoma receiving pembrolizumab (Keytruda) after only one week—rather tha

Updated on: May 06,2024

Imaging after one week on pembrolizumab may predict treatment response in advanced melanoma

by American Association for Cancer ResearchCredit: Pixabay/CC0 Public DomainImaging the tumors of patients with advanced melanoma receiving pembrolizumab (Keytruda) after only one week—rather tha

Updated on:May 06,2024

A predictive biomarker of response to therapy in patients with microsatellite stable metastatic colorectal cancer

by Vall d'Hebron Institute of OncologyA total of 166 patients with mCRCBRAF-V600Ewere included in the study from discovery (n = 46), validation (n = 52) and control (n = 68) cohorts. WES of

Updated on: January 08,2024

A predictive biomarker of response to therapy in patients with microsatellite stable metastatic colorectal cancer

by Vall d'Hebron Institute of OncologyA total of 166 patients with mCRCBRAF-V600Ewere included in the study from discovery (n = 46), validation (n = 52) and control (n = 68) cohorts. WES of

Updated on:January 08,2024

How a little-known glycoprotein blocks a cancer cell's immune response

by University of MichiganThe interaction between STC1 and calreticulin. Credit: University of Michigan Rogel Cancer CenterIt was an unexpected discovery that started with an analysis of more than

Updated on: March 26,2024

How a little-known glycoprotein blocks a cancer cell's immune response

by University of MichiganThe interaction between STC1 and calreticulin. Credit: University of Michigan Rogel Cancer CenterIt was an unexpected discovery that started with an analysis of more than

Updated on:March 26,2024

Study highlights the importance of infection prevention after CAR T-cell therapy

Study highlights the importance of infection prevention after CAR T-cell therapybyDana-Farber Cancer InstituteDistribution of causes of nonrelapse deaths across treatment settings and disease en

Updated on: July 09,2024

Study highlights the importance of infection prevention after CAR T-cell therapy

Study highlights the importance of infection prevention after CAR T-cell therapybyDana-Farber Cancer InstituteDistribution of causes of nonrelapse deaths across treatment settings and disease en

Updated on:July 09,2024

Time for a 'Weed-Free January?' How cannabis users could benefit from a 'dry' month

by James MacKillop,The ConversationCredit: RDNE Stock project from PexelsBy now, most are familiar with the idea of Dry January, a voluntary month without alcohol that follows a month when many

Updated on: March 26,2024

Time for a 'Weed-Free January?' How cannabis users could benefit from a 'dry' month

by James MacKillop,The ConversationCredit: RDNE Stock project from PexelsBy now, most are familiar with the idea of Dry January, a voluntary month without alcohol that follows a month when many

Updated on:March 26,2024

Addition of durvalumab, bevacizumab to TACE beneficial in liver cancer

by Elana GotkineFor patients with embolization-eligible unresectable hepatocellular carcinoma (uHCC), the addition of durvalumab (D) and bevacizumab (B) to transarterial chemoembolization (TACE) impro

Updated on: March 22,2024

Addition of durvalumab, bevacizumab to TACE beneficial in liver cancer

by Elana GotkineFor patients with embolization-eligible unresectable hepatocellular carcinoma (uHCC), the addition of durvalumab (D) and bevacizumab (B) to transarterial chemoembolization (TACE) impro

Updated on:March 22,2024